

DEMODICOSIS SARCOPTIC MANGE

MORE THAN
97%
EFFICACY
IN 3 MONTHS
(3-7)



NexGard[®]

NexGard[®]
SPECTRA[®]

VISIBLE EFFICACY
IMPRESSIVE RESULTS



DEMODICOSIS: A COMMON DISEASE IN CANINE PRACTICE

A SEVERE AND COMPLEX DISEASE

- Canine demodicosis is often a very severe parasitic skin disease which is challenging to treat
- Signs develop after significant mite proliferation and vary greatly, depending on multiple factors:
 - Degree of mite proliferation
 - Dog susceptibility
 - Underlying conditions
 - Chronicity
- The disease can be expressed as:
 - Localised form with superficial papules, pustules and focal alopecia
 - Generalised form involving large areas of the body. Severe secondary bacterial infections and life threatening systemic signs may occur

5 TIPS TO SUSPECT DEMODICOSIS

- 1 Any dog under 18 months
- 2 Dogs over 18 months with concurrent disease or immunosuppressive treatment
- 3 Hair-loss /alopecia, associated or not with inflammatory dermatitis, erythema, comedones, scaling
- 4 Focal lesions or multifocal to coalescing lesions involving large areas of the body
- 5 Pedal marked hyperpigmentation associated or not with interdigital inflammation, oedema and pain



HOW TO DIAGNOSE DEMODICOSIS?

DIAGNOSIS⁽¹⁾ IS BASED ON

- **Medical history**
- **Clinical signs**
- **Detection of *Demodex* mites at different stages of their life cycle: more than one mite found is an indication of clinically relevant demodicosis**
 - Method of choice: skin scrapings
 - Trichograms: useful in areas that are difficult to scrape (periorcular and interdigital areas)
 - Tape strips (after skin squeezing) and examinations of exudate may be useful

DIFFERENTIAL DIAGNOSIS

- Atopic dermatitis, deep pyoderma...
- Other parasitic diseases (sarcoptic mange, dermatophytosis, leishmaniosis...)

SKIN SCRAPING TECHNIQUE



Primary lesions (follicular papules and pustules) should be selected in order to obtain the best yield. Ulcerated areas are not suited.

Press the skin to extrude the mites from the depth of the follicles to the surface.



Scrape the skin until capillary bleeding occurs (sufficient depth of the scraping).

Multiple scrapings of approximately 1 cm² of affected skin should be performed.

HAIR PLUCKING FOR TRICHOGRAM



An area of 1cm² should be plucked with forceps.

Sufficient number of hairs (50-100) should be plucked.

DEMODICOSIS TREATMENT AND FOLLOW-UP

Generalised demodicosis, with or without secondary bacterial infection, pododemodicosis and aural demodicosis, must be treated. Localised forms of demodicosis may resolve spontaneously but must be monitored closely.⁽¹⁾


TREATMENT

- Duration is often long, sometimes several months
In a retrospective US study⁽²⁾, following various miticidal treatments of dogs diagnosed with generalised demodicosis, juvenile demodicosis was treated within 4.5 months. Adult demodicosis was treated within 5.9 months
- Until recently, few effective acaricidal formulations were available

PRINCIPLES OF TREATMENT MONITORING FOR DEMODICOSIS

Monthly follow-up is recommended.

Adapted from the WAVD Clinical Consensus Guidelines for Demodicosis⁽¹⁾.



5 TIPS FOR THE FOLLOW-UP




Monthly evaluation of clinical improvement



Numbers of mites should decrease at each visit




In case of relapse check for underlying disease



Acaricidal therapy should be continued a month beyond the second set of negative monthly scrapings to decrease the risk of relapse



Follow-up 12 months after treatment cessation is recommended before calling a dog cured



CHECK FOR UNDERLYING CONDITIONS

* In dogs responding very slowly to therapy, treatment may be extended even further.

DEMODICOSIS: EFFICACY OF NEXGARD® AND NEXGARD SPECTRA®

SUMMARY OF STUDY DESIGNS

- Two experimental controlled studies^(3,4) and one field study⁽⁵⁾ were conducted
- The European multicentric field efficacy trial was conducted in 6 dermatology referral centers from France, Italy and Poland⁽⁵⁾
- A total of 74 dogs were treated with afoxolaner in these studies:
 - 47 treated with afoxolaner alone (NexGard®)^(3, 5)
 - 27 treated with afoxolaner + milbemycin oxime (NexGard Spectra®)^(4,5)
- All the studies had a duration of 3 months

SUMMARY OF RESULTS



REDUCTION IN MITE COUNTS AFTER 3 MONTHLY TREATMENTS


	NexGard®	NexGard SPECTRA®
STUDY 1 ⁽³⁾	100%	Not tested
STUDY 2 ⁽⁴⁾	99.9%	100%
STUDY 3 ⁽⁵⁾	98.2%	97.5%

MORE THAN
97%
EFFICACY
AFTER 3 MONTHS
(3,4,5)



EUROPEAN PICTURE OF DEMODICOSIS IN THE FIELD STUDY

HIGHLIGHT OF THE STUDY



> Breeds



Enrolled dog population reflected the profile of dogs usually presented for demodicosis in veterinary practices


> Demodectic podal dermatitis was more difficult to cure

14 dogs enrolled had demodectic podal dermatitis. Seven of these dogs were among the dogs still harboring live mites at the end of the study

IMPROVEMENT OF CLINICAL SIGNS

Clinical evolution after monthly administrations of afoxolaner in two dogs with generalised demodicosis⁽⁵⁾





SARCOPTIC MANGE

A HIGHLY CONTAGIOUS, INTENSELY PRURITIC PARASITIC SKIN DISEASE

Caused by infestation with the epidermal mite *Sarcoptes scabiei var. canis*.

DIAGNOSIS IS BASED ON

› Clinical signs

- Severe pruritus
- Erythematous rash and yellowish crusts on the skin, starting with ear tips, elbows, hocks (ankles), belly and chest

› **Detection of mites**, but even deep skin scrapings do not always reveal their presence

› **Serology** may be of interest to confirm clinical suspicion in case of negative scrapings

FURTHER CONSIDERATIONS

› **Due to the contagious nature of disease, all in-contact dogs should be treated**

› Maintaining skin health

Shampooing or bathing with medicated or non-medicated formulations to rehydrate the skin and treat seborrhea

These procedures may reduce the efficacy or shorten the activity of topical products



EFFICACY OF NEXGARD® AND NEXGARD SPECTRA® AGAINST SARCOPTES SCABIEI INFESTATION

- Study 1: Initial controlled field study conducted with afoxolaner (NexGard®) in 10 client owned dogs⁽⁶⁾
- Study 2: Large scale field study using afoxolaner involving 8 clinical centers in Portugal and Germany, with 80 client owned dogs enrolled⁽⁷⁾ treated either with afoxolaner (NexGard®) or afoxolaner + milbemycin oxime (NexGard Spectra®)

Results:

- ≥98.9% efficacy obtained against mites as soon as after the first treatment⁽⁶⁻⁷⁾
- High score of resolution in skin lesions and pruritus in 2 months



REDUCTION IN MITE COUNTS AT THE END OF EACH 2 MONTHS STUDY


	NexGard®	NexGard SPECTRA®
STUDY 1 ⁽⁶⁾	100%	Not tested
STUDY 2 ⁽⁷⁾	99.7%	100%

IMPROVEMENT OF CLINICAL SIGNS

BEFORE



AFTER



Study 1

Clinical appearance of a dog with sarcoptic mange:

Left: pretreatment (Day 0)
Right: day 56

DAY 0



DAY 28



DAY 56



Study 2

Clinical evolution from day 0 (pretreatment) to day 28 (after one NexGard® treatment) and day 56 (after 2 NexGard® treatments)

NEXGARD® & NEXGARD SPECTRA®: MONTHLY DOSING FOR CONVENIENT MITE TREATMENT

MONTHLY TREATMENTS OF MITE INFESTATIONS

➤ A treatment administrated at a monthly interval:

- Fits with monthly re-check of mite infestation

➤ NexGard Spectra® allows veterinarians to adapt the treatment of demodicosis or sarcoptic mange to specific epidemiological situations:


- Heartworm or lungworm disease enzootic areas
- Deworming against gastrointestinal worms, including roundworms, hookworms, whipworm



NEXGARD® & NEXGARD SPECTRA®: THE RIGHT DOSE AT THE RIGHT TIME

- ### ➤ Controlled dosage: no great variation in Cmax during treatment, regulated plasma concentration and speed of elimination

Registration dossier



- ### ➤ No significant variation of bioavailability after administration: the treatment can be administered with or without food



REFERENCES

1. R.S. Mueller, W. Rosenkrantz, E. Besignor, J. Karaš-Tecza, T. Paterson and M. Shipstone. 2018 WAVD Clinical consensus guidelines for demodicosis. <https://wavd.org/continuing-education/consensus-guidelines/>
2. Daniel G Bowden, Catherine A. Outerbridge, Marguerite B. Kissel, Jerome N. Baron and Stephen D. White. Canine demodicosis: a retrospective study of a veterinary hospital population in California, USA (2000–2016). *Veterinary Dermatology* 2018; 29: 19–e10.
3. Beugnet F, Halos L, Larsen D, de Vos C. Efficacy of oral afoxolaner for the treatment of canine generalised demodicosis. *Parasite* 2016 23, 14.
4. Steffen Rehbein, Christa de Vos, Frédéric Beugnet, Doug Carithers, Josephus Fourie. Efficacy of once-monthly doses of oral afoxolaner and afoxolaner/milbemycin oxime in a well-controlled study for the treatment of canine generalised demodicosis. *Open Journal of Veterinary Medicine*, 2018, 8, 250-265.
5. Wilfried Lebon, Massimo Beccati, Patrick Bourdeau, Thomas Brement, Vincent Bruet, Agnieszka Cekiera, Odile Crosaz, Céline Darmon, Jacques Guillot, Marion Mosca, Didier Pin, Jaroslaw Popiel, Dorota Pomorska Handwerker, Diane Larsen, Eric Tielemans, Frédéric Beugnet and Lénaïg Halos. Efficacy of two formulations of afoxolaner (NexGard® and NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe. *Parasites & Vectors* 2018 11:506.
6. Beugnet F, de Vos C, Liebenberg L, Halos L, Diane D, Fourie J. Efficacy of afoxolaner in a clinical field study in dogs naturally infested with *Sarcoptes scabiei*. *Parasite*. 2016 23, 26.
7. Verena Hampel, Jürgen Schäfer, Martin Knäus, Frederic Beugnet, Steffen Rehbein. Treatment of canine sarcoptic mange with afoxolaner (NexGard®) and afoxolaner plus milbemycin oxime (NexGard Spectra®) chewable tablets: efficacy under field conditions. Treatment of canine sarcoptic mange with afoxolaner (NexGard Spectra®) and afoxolaner plus milbemycin oxime (NexGard Spectra®) chewable tablets: efficacy under field conditions in Portugal and Germany. *Parasite* 2018 25, 63.

NexGard® 11 mg chewable tablets for dogs 2-4 kg, 28 mg chewable tablets for dogs > 4-10 kg, 68 mg chewable tablets for dogs > 10-25 kg, 136 mg chewable tablets for dogs > 25-50 kg. Each tablet contains afoxolaner. UK: POM-V IE: POM. Indications for use: Treatment of flea infestation in dogs (*Ctenocephalides felis* and *C. canis*) for at least 5 weeks, can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). Treatment of tick infestation in dogs (*Dermacentor reticulatus*, *Ixodes ricinus*, *Ixodes hexagonus*, *Rhipicephalus sanguineus*). One treatment kills ticks for up to one month. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. Treatment of demodicosis (caused by *Demodex canis*). Treatment of sarcoptic mange (caused by *Sarcoptes scabiei var. canis*). **For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet. Use medicines responsibly.**

NexGard Spectra® 9 mg / 2 mg chewable tablets for dogs 2-3.5 kg; 19 mg / 4 mg chewable tablets for dogs >3.5-7.5 kg; 38 mg / 8 mg chewable tablets for dogs >7.5-15 kg; 75 mg / 15 mg chewable tablets for dogs >15-30 kg; 150 mg / 30 mg chewable tablets for dogs >30-60 kg. Each chewable tablet contains Afoxolaner and Milbemycin oxime. UK: POM-V IE: POM. Indications for use: For the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease (*Dirofilaria immitis* larvae), angiostrongylosis (reduction in level of immature adults (L5) and adults of *Angiostrongylus vasorum*), thelaziosis (adult *Thelazia callipaeda*) and/or treatment of gastrointestinal nematode infestations is indicated. Treatment of flea infestations (*Ctenocephalides felis* and *C. canis*) in dogs for 5 weeks. Treatment of tick infestations (*Dermacentor reticulatus*, *Ixodes ricinus*, *Ixodes hexagonus*, *Rhipicephalus sanguineus*) in dogs for 4 weeks. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. Treatment of demodicosis (caused by *Demodex canis*). Treatment of sarcoptic mange (caused by *Sarcoptes scabiei var. canis*). Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (*Toxocara canis* and *Toxascaris leonina*), hookworms (*Ancylostoma caninum*, *Ancylostoma braziliense* and *Ancylostoma ceylanicum*) and whipworm (*Trichuris vulpis*). Prevention of heartworm disease (*Dirofilaria immitis* larvae) with monthly administration. Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of *Angiostrongylus vasorum*) with monthly administration. Prevention of establishment of thelaziosis (adult *Thelazia callipaeda* eyeworm infection) with monthly administration.

For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet. Advice on the use of these or alternative medicines must be sought from the medicine prescriber. Use medicines responsibly

© 2019 Boehringer Ingelheim Animal Health. This brochure has been produced by Boehringer Ingelheim Global Veterinary Technical Services for international events only.

NEXGARD® RANGE:

CONVENIENCE, TASTY, EFFICACY



FLEA & TICK CONTROL
IN A TASTY CHEW

... AND
AGAINST
DEMODICOSIS
AND
SARCOPTIC
MANGE



INTERNAL AND EXTERNAL
PARASITE CONTROL
WITH A SINGLE SIMPLE
SOLUTION

ACTIVE:
Afoxolaner

MODE OF ACTION:
Systemic

ADMINISTRATION:
Oral, monthly* dosing for a regular
reloading of afoxolaner & a sustainable
efficacy month after month

PRESENTATION: 4 sizes
2-4kg | 4.1-10kg
10.1-25kg | 25.1-50kg

ECTO COVER:



- ✓ 1 month flea and tick efficacy
- ✓ Demodicosis and Sarcoptic mange treatment

ACTIVES:
Afoxolaner + milbemycin oxime

MODE OF ACTION:
Systemic

ADMINISTRATION:
Oral, monthly* dosing for a regular
reloading of afoxolaner & a sustainable
efficacy month after month

PRESENTATION: 5 sizes
2-3.5kg | 3.5-7.5kg | 7.5-15kg
15-30kg | 30-60kg

ECTO COVER:



- ✓ 1 month flea and tick efficacy
- ✓ Demodicosis and Sarcoptic mange treatment

ENDO COVER:



- ✓ Broad protection against most frequent or life threatening internal parasites



* Treatment schedule should be based on veterinary diagnosis and on the local epidemiological situation